rethinkTHC Search
Menu
Study breakdown

Review: Endocannabinoid System Could Address IBD Complications Beyond the Gut

Narrative ReviewLow evidence
The takeaway

A comprehensive review found the endocannabinoidome — a network of cannabinoid receptors, lipid mediators, and enzymes — shows promise for managing IBD complications in the joints, skin, liver, and eyes, not just intestinal inflammation.

gastroenterologists, rheumatologists, cannabinoid researchers, IBD patients with extraintestinal symptoms

What the researchers found

The endocannabinoidome (eCBome) includes receptors (CB1, CB2, GPR55, GPR35, PPARα, TRPV1), lipid mediators, and metabolic enzymes that modulate immune responses, gut barrier integrity, and systemic inflammation. Targeting eCBome may improve both intestinal inflammation and extraintestinal manifestations including arthritis, liver dysfunction, and dermatological disorders.

Why it matters

IBD is not just a gut disease — many patients suffer from joint, skin, liver, and eye complications that standard intestinal therapies do not address. The endocannabinoidome offers a unified therapeutic target for both local and systemic disease components.

The numbers in context

Receptors reviewed: CB1, CB2, GPR55, GPR35, PPARα, TRPV1. Extraintestinal targets: joints (arthritis), skin (dermatological disorders), liver (dysfunction), eyes. Multiple metabolic enzymes and lipid mediators assessed.

How the study worked

Comprehensive literature review across PubMed, Scopus, Web of Science, Science Direct, and Google Scholar. Focused on endocannabinoidome role in IBD and extraintestinal manifestations.

What this study cannot tell us

Narrative review without systematic methodology. Much evidence is preclinical. Clinical evidence for eCBome-targeting therapies in IBD extraintestinal manifestations is very limited. Complex system makes targeted drug development challenging.

How to read the evidence

Comprehensive narrative review identifying promising targets, but most evidence is preclinical and clinical validation is minimal.

When this study was published

2025 publication.

The bigger picture

Moving beyond the traditional focus on CB1 and CB2 receptors to the broader endocannabinoidome opens new therapeutic possibilities. Understanding the full network of cannabinoid-related signaling could lead to more targeted treatments with fewer side effects.

Questions still open

  • Which eCBome targets are most clinically promising for IBD extraintestinal complications?
  • Could a single eCBome-targeting drug address both intestinal and extraintestinal IBD?

Common questions

Can cannabinoids help with IBD joint pain?
This review found the endocannabinoidome plays a role in modulating joint inflammation and could potentially address IBD-related arthritis. However, clinical evidence for this specific application is still very limited.
Why does IBD cause problems outside the gut?
IBD involves systemic immune dysregulation, causing complications in joints, skin, liver, and eyes. This review found the endocannabinoidome — a network including CB1, CB2, and other receptors — regulates both gut and systemic inflammation, making it a promising target for comprehensive IBD treatment.

Read the original research

Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.

Pharmaceuticals (Basel, Switzerland), 18(4)

Citation

Thapa, Dinesh; Ghimire, Anjali; Warne, Leon N; Carlessi, Rodrigo. (2025). Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease.. Pharmaceuticals (Basel, Switzerland), 18(4). https://doi.org/10.3390/ph18040478

Explore the wider topic